Moreover, another tumor-homing peptide, LyP-1 (CGNKRTRGC), capable of targeting the cell surface of localized C1QBP, has been used to deliver nanoparticles to breast tumors overexpressing C1QBP and has shown efficacy in vivo (Luo et al., 2010). The gene discussed is PTPN22; the disease is neoplasm.